Golodirsen增加Duchenne肌营养不良患者的抗肌萎缩蛋白生成
本研究报道golodirsen在适合外显子53跳跃的Duchenne肌营养不良患者中的安全性、药代动力学、外显子跳跃和抗肌萎缩蛋白表达。第1部分为随机双盲安慰剂对照12周剂量滴定,第2部分为开放标签评估。结果显示golodirsen耐受良好,肌肉活检显示外显子53跳跃增加、抗肌萎缩蛋白生成增加及正确的肌膜定位。
要点
- Golodirsen耐受性良好,安全性与此前儿科DMD患者观察一致。
- 第48周时抗肌萎缩蛋白表达较基线增加约16倍,平均正常标准百分比为1.019%。
- 外显子53跳跃显著增加,抗肌萎缩蛋白阳性纤维显著增加并与蛋白变化正相关。
核心结论
- Golodirsen耐受良好,并诱导外显子53跳跃、抗肌萎缩蛋白生成及正确的肌膜定位。
研究设计与样本
- 第1部分为随机、双盲、安慰剂对照、12周剂量滴定,每周一次golodirsen;第2部分为正在进行的开放标签评估。
- 第1部分12例患者随机接受golodirsen(n=8)或安慰剂(n=4);第1部分全部患者加13例额外患者在第2部分接受30 mg/kg golodirsen。
主要发现
- 大多数研究药物在给药后4小时内排泄。
- 第48周时外显子53跳跃显著增加,抗肌萎缩蛋白表达较基线增加约16倍,平均正常标准百分比为1.019%(范围0.09%-4.30%)。
- 第48周抗肌萎缩蛋白阳性纤维显著增加(p < 0.001),且与Western blot和免疫组化测定的抗肌萎缩蛋白变化呈正相关(Spearman r = 0.663;p < 0.001)。
关键数值与推荐
- 第2部分主要生物学结局指标为盲法评估的外显子跳跃和肌肉活检(基线、第48周)的抗肌萎缩蛋白生成,分别采用逆转录PCR和Western blot及免疫组化评估。
临床怎么用
- 对于适合外显子53跳跃的DMD患者,golodirsen可增加抗肌萎缩蛋白生成并正确定位于肌膜。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report safety, pharmacokinetics, exon 53 skipping, and dystrophin expression in golodirsen-treated patients with Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping. METHODS: Part 1 was a randomized, double-blind, placebo-controlled, 12-week dose titration of once-weekly golodirsen; part 2 is an ongoing, open-label evaluation. Safety and pharmacokinetics were primary and secondary objectives of part 1. Primary biological outcome measures of part 2 were blinded exon skipping and dystrophin protein production on muscle biopsies (baseline, week 48) evaluated, respectively, using reverse transcription PCR and Western blot and immunohistochemistry. RESULTS: Twelve patients were randomized to receive golodirsen (n = 8) or placebo (n = 4) in part 1. All from part 1 plus 13 additional patients received 30 mg/kg golodirsen in part 2. Safety findings were consistent with those previously observed in pediatric patients with DMD. Most of the study drug was excreted within 4 hours following administration. A significant increase in exon 53 skipping was associated with ∼16-fold increase over baseline in dystrophin protein expression at week 48, with a mean percent normal dystrophin protein standard of 1.019% (range, 0.09%-4.30%). Sarcolemmal localization of dystrophin was demonstrated by significantly increased dystrophin-positive fibers (week 48, p < 0.001) and a positive correlation (Spearman r = 0.663; p < 0.001) with dystrophin protein change from baseline, measured by Western blot and immunohistochemistry. CONCLUSION: Golodirsen was well-tolerated; muscle biopsies from golodirsen-treated patients showed increased exon 53 skipping, dystrophin production, and correct dystrophin sarcolemmal localization. CLINICALTRIALSGOV IDENTIFIER: NCT02310906. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that golodirsen is safe and Class IV evidence that it induces exon skipping and novel dystrophin as confirmed by 3 different assays.
引用
- Frank DE, Schnell FJ, Akana C, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020. PMID: 32139505. doi:10.1212/WNL.0000000000009233
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。